MiRNAs are short, endogenous, noncoding RNAs that regulate gene expressions at the posttranscriptional level by binding to the 3′-untranslated regions of their target mRNAs. 6, 7 MiRNAs have now emerged as key regulators of cardiac growth, vascular development, and angiogenesis. 8, 9 Recent studies demonstrated that miRNAs can be detected in circulating blood and may be useful as disease biomarkers. 10, 11 The levels and identities of circulating miRNAs in cardiovascular diseases have been evaluated in a series of studies. For instance, levels of some vascular and inflammation-associated miRNAs were found to be significantly lower in the plasma of 67 patients with CHD when compared with controls, 12 and the cardiac-specific miRNA, miR-208a, was only detectable in 33 patients with AMI and not Background-Circulating microRNAs ( miRNAs) are emerging as novel disease biomarkers. We aimed to explore the association between circulating miRNAs and the occurrence of acute myocardial infarction (AMI) in Chinese populations. Methods and Results-In the discovery stage, the plasma of 20 patients with AMI and 20 controls were pooled respectively and profiled by massively parallel sequencing. Seventy-seven miRNAs showed differential expression. Selected miRNAs were validated in 178 patients with AMI and 198 controls using quantitative reverse transcriptase polymerase chain reaction assays and further replicated in 150 patients with AMI and 150 controls. Results suggest that miR-320b and miR-125b levels were significantly lower in patients with AMI than in controls in both validation populations (P<0.0001). Lower levels of miR-320b and miR-125b were associated with increased occurrence of AMI (adjusted odds ratio, 4.71; 95% confidence interval, 2.96-7.48 and odds ratio, 4.27; 95% confidence interval, 2.84-6.41, respectively). Addition of the 2 miRNAs to traditional risk factors led to a significant improvement in the area under the curve from 0.822 (95% confidence interval, 0.787-0.856) to 0.871 (95% confidence interval, 0.842-0.900), with a net reclassification improvement of 20.45% (P<0.0001) and an integrated discrimination improvement of 0.16 (P<0.0001) for patients with AMI. A functional study showed that miR-320b and miR-125b could regulate the expression profiles of genes enriched in several signal transduction pathways critical for coronary heart disease in human vascular endothelial cells. Conclusions-The plasma levels of miR-320b and miR-125b were significantly lower in patients with AMI when compared with controls, and these miRNAs may be involved in the pathogenesis of coronary heart disease. (Circ Cardiovasc Genet. 2014;7:189-198.)
A cute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide. 1 Multiple conventional risk factors and serum atherosclerotic biomarkers have been established for coronary heart disease (CHD). 2 However, advances in genomics and proteomics, especially gene-expression profiling using microarray and quantitative real-time polymerase chain reaction (qPCR), have promoted the generation of many novel molecular biomarkers for AMI with potential clinical values. 3, 4 Recently, microRNAs (miRNAs) have attracted extensive interest in the field of cardiovascular diseases. 5 in the 33 patients with non-AMI or in the 30 healthy subjects. 13 However, the sample sizes of these studies were small, and the roles of plasma miRNAs in AMI remain to be determined. Therefore, we tested the difference in levels of plasma miRNAs between 2 plasma pools from 20 patients with AMI and 20 healthy controls using massively parallel sequencing followed by individual quantitative reverse transcriptase PCR (qRT-PCR) assays. Two differentially expressed miRNAs were validated in 178 patients with AMI and 198 healthy controls and further replicated in 150 patients with AMI and 150 healthy controls. Associations between the miRNAs and AMI were analyzed by 2 multivariate logistic regression models. Moreover, inspired by the intriguing finding that circulating miRNAs can be transferred to the recipient vascular endothelial cells (VECs) and act as gene regulators in the pathogenesis of atherosclerosis, 14 the potential biological functions of miR-320b and miR-125b were evaluated in human umbilical vein endothelial cells (HUVECs) by exploring their effects on gene-expression profiles using Affymetrix Gene Chip. Furthermore, these 2 miRNAs were detected in 100 patients with stable CHD serving as the patient control for AMI and were compared with the patients with AMI and controls.
Methods

Study Design and Populations
A flow diagram representing the study design is shown in Figure 1 . An initial screening of genome-wide plasma miRNA expression profiles (discovery stage) followed by 2 independent case-control studies (validation stages I and II) were performed. The general characteristics of the 3 population cohorts are provided in Table I in the Data Supplement. Patients with AMI in the discovery stage and validation stage I were consecutively recruited from Wuhan Tongji and Union Hospitals between 2008 and 2010. Patients in validation stage II were recruited from Wugang Hospital between 2008 and 2010. Patients who had received intravenous thrombolytic or anticoagulant therapy (including heparin) before blood sampling were excluded. Subjects were classified as AMI as previously described. 15, 16 Briefly, the diagnosis of AMI was based on the following criteria: (1) chest pain lasting >20 minutes, (2) pathological Q waves or ST-segment elevation/depression on the ECG, and (3) elevation of traditional myocardial markers. The patients with stable CHD and chest pain were recruited from Wuhan Tongji and Union Hospitals between 2008 and 2010 after angiographic documentation of CHD (stenosis ≥50% in ≥1 major coronary artery). Patients with impaired ejection fraction, heart failure, unstable CHD, or acute myocardial injury were excluded. Healthy subjects without medical history of cardiovascular diseases were selected as controls during a physical health examination at the hospital, and they were matched by age, sex, and area of residence with the patients. About 5 mL of vein blood samples were collected from each participant in EDTA-anticoagulant tubes. The blood samples of patients with AMI were collected within 12 hours after chest pain, and the average period of time from symptom onset to blood sampling was 6.9±2.2 hours. Plasma was isolated from the whole blood samples by centrifugation at 1600g for 10 minutes at 4°C first, and the plasma samples were transferred to a clean 1.5-mL centrifugal tube and subjected to a second round of centrifugation at 16 000g for 10 minutes at 4°C.
For all participants, structured questionnaires were used to collect information on their demographic characteristics and clinical biochemistry by trained interviewers. The ethics committee of Tongji Medical College approved this study, and written informed consent was obtained from each participant.
Plasma RNA Isolation
The detailed information for RNA isolation is shown in Materials in the Data Supplement. About 25 fmol of synthetic Caenorhabditis elegans cel-miR-39 (Qiagen) was added to the denatured plasma samples, serving as the internal control for validation studies (Figure I in the Data Supplement). 11 Figure 1 . Study design. AMI indicates acute myocardial infarction; miRNAs, microRNAs; and qRT-PCR, quantitative reverse transcriptase polymerase chain reaction.
Massively Parallel Sequencing and miRNA Selection Criteria
The massively parallel sequencing was performed as described previously. 10 We calculated the normalized copy number for each miRNA by the equation (C×10 6 )/N, in which C means the number of reads mapped to individual miRNA, and N means the total number of aligned reads. We selected the differentially expressed miRNAs for validation, which had ≥50 copies in either AMI or control group and showed ≥4-fold altered expression between the 2 pooled samples.
qRT-PCR Assays
The expression levels of the selected miRNAs were measured by qRT-PCR assays. The detailed information for qRT-PCR assays is shown in Materials in the Data Supplement. miRNA expression levels were normalized to cel-miR-39 and calculated by the equation 2 -ΔCt , where ΔCt=cycle threshold (Ct) (miRNA) -Ct (cel-miR-39) .
Gene-Expression Microarray and Bioinformatics Analysis
HUVECs were transfected with 50 nmol/L miR-320b mimics, miR-125b mimics, or mimic controls (Ribo Bio Co, Ltd, Guangzhou, China) for 48 hours (in triplicates). Gene-expression profiling of the total 9 samples was performed by the Affymetrix Gene Chip. In brief, total RNA was extracted from cultured cells using the miRNeasy Mini Kit (Qiagen). The quality and quantity of RNA were determined using Agilent 2100 Bioanalyzer and Nanodrop ND-1000. One hundred nanograms of total RNA were used to prepare cDNA after the Affymetrix 3'IVT Express Kit labeling protocol. Standardized array processing procedures recommended by Affymetrix, including hybridization, fluidics processing, and scanning, were used. Normalization of the data was done with the program RMA. 17, 18 The criteria for the differentially expressed genes were a fold change ≥2 or ≤0.5 and the false discovery rate <0.05 considering multiple comparisons. The gene functions were annotated by gene ontology (GO) mapping (http://www.geneontology.org/). The pathway enrichment of the differentially expressed genes was analyzed by Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome. jp/kegg/). All the bioinformatics analysis was performed by the DAVID tools (http://david.abcc.ncifcrf.gov/).
Statistical Analysis
The normal distribution of data was tested by the 1-sample Kolmogorov-Smirnov test. The continuous variables were expressed as mean±SD or median (25th-75th quartile). The correlation of plasma miRNA profiles (log-transformed and normally distributed) between cases and controls was analyzed by Pearson correlation test. Differences in clinical characteristics and circulating miRNA levels between cases and controls were examined by the χ 2 test for categorical variables or by Student t test for normally distributed data, as well as by the Mann-Whitney U test for skewed data. Differences in clinical characteristics among the 3 patient cohorts were examined by the χ 2 test for categorical variables, by 1-way analysis of variance for normally distributed data, and by Kruskal-Wallis H test for skewed data. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between circulating miRNAs and AMI with the multivariate logistic regression model after adjusting for conventional CHD risk factors, including age, sex, smoking status, total cholesterol, triglyceride, body mass index, hypertension, and diabetes mellitus. Model 2 was additionally adjusted for history of medication use before hospital admission, specifically antihypertensive drugs and cholesterol-lowering agents. The median levels of circulating miRNAs in the control subjects of validation stage I were used as the cutoff value to stratify miRNAs for the association analysis in all studies. The ability of circulating miRNAs to discriminate patients with AMI from controls or to reclassify patients with AMI was determined by the receiver operating characteristic curve and reclassification analysis using 2 models: one was a baseline model, including the conventional CHD risk factors and history of medication use, and the other model incorporated the factors in the baseline model and miRNA expressions. Correlations between circulating miRNAs and cardiac enzymes were analyzed by the Spearman correlation test. The differences in gene-expression profiles in HUVECs were examined by the Student t test. Differences in miR-125b and miR-320b between categories of healthy control, stable CHD, and AMI were compared with general linear models after adjustment with conventional risk factors and history of medication use. All statistical analyses were performed using SPSS 11.0 software (Statistical Package for the Social Sciences, Chicago, IL), except for the false discovery rate analysis of the differentially expressed genes by R statistical software. A value of P<0.05 or false discovery rate <0.05 was considered significant (2-tailed).
Results
Characteristics of the Study Populations
The general characteristics of the populations are shown in Table 1 . Patients and controls were matched by age and sex in the 3 populations. We also compared the general characteristics among the 3 patient cohorts as shown in Table I in the Data Supplement. Age, sex, total cholesterol, high-density lipoprotein cholesterol levels, the history of hypertension and diabetes mellitus, and the cholesterol-lowering agent usage differed among the 3 cohorts (P<0.05). However, the other variables showed no significant difference.
Plasma miRNA Profiles in Patients With AMI Versus Controls
The plasma miRNA profiles of patients with AMI and controls detected by massively parallel sequencing are shown in Figure II in the Data Supplement. Among the 1100 detected miRNAs, 205 miRNAs were detected in controls and 210 in patients with AMI, respectively. Levels of circulating miRNAs of the 2 groups were correlated (r=0.53). Notably, 77 miRNAs differed >2-fold ( Figure 2 ) between patients with AMI and controls. According to the miRNA selection criteria, 5 miRNAs with the largest fold changes (2 downregulated and 3 upregulated) were detected by qRT-PCR assays ( Table II in the Data Supplement). Results suggested that the plasma levels of 2 miRNAs (miR-125b and miR-320b) were significantly lower in patients with when compared with that in controls (P<0.001 for miR-125b and P=0.001 for miR-320b).
Validation Stage I
We further validated the expression of the 2 miRNAs in a larger population (including 198 controls and 178 patients with AMI, validation stage I). As shown in Figure 3A , the expression level of miR-320b was 3.46-fold decreased in patients with AMI when compared with the controls (logtransformed expression levels, -1.94±0.67 versus -1.43±0.56; P<0.0001), and miR-125b showed a 3.17-fold decreased expression level in patients with AMI when compared with the controls (log-transformed expression levels, -3.38±0.85 versus -2.89±0.77; P<0.0001). No significant difference was found in the miRNA expression levels between patients with or without drug uses before hospital admission ( 
Validation Stage II and Pooled Analysis
We further validated the expressions of miR-320b and miR-125b in validation stage II population (including 150 controls and 150 patients with AMI). The expression levels of the 2 miRNAs were consistently lower in patients with AMI when compared with controls (log-transformed expression levels, -2.41±0.65 versus -1.69±0.64; P<0.0001 for miR-320b and -3.57±0.76 versus -2.71±0.81; P<0.0001 for miR-125b, respectively; Figure 3B ). MiR-320b/ miR-125b showed a 5-or 7.15-fold decreased expression level in patients with AMI when compared with the control subjects. Medication use did not alter the miRNA expression levels in patients with AMI ( 
Diagnostic Value of the 2 MiRNAs by Receiver Operating Characteristic Curve and Reclassification Analysis
We next examined whether addition of miRNAs improved the discrimination or reclassification of patients with AMI in the combined population (Table 3) . Results suggest that the area under the receiver operating characteristic curve was 0.822 (95% CI, 0.787-0.856) for the baseline model and significantly increased to 0.866 (95% CI, 0.836-0.896), 0.858 (95% CI, 0.827-0.889), and 0.871 (95% CI, 0.842-0.900) when miR-320b, miR-125b, or both of them were added to the prediction model (P=0.0016, 0.0036, and 0.0005, respectively).
The net reclassification improvement and integrated discrimination improvement were computed to determine the ability of miRNAs to reclassify patients misclassified by the baseline model correctly. MiR-320b and miR-125b were able to reclassify a significant portion of patients with a net reclassification improvement of 18.26% (95% CI, 10.54%-25.99%; P<0.0001) and 14.88% (95% CI, 8.12%-21.64%; P<0.0001), respectively. The integrated discrimination improvement for the 2 miRNAs was 0.15 (95% CI, 0.12-0.19; P<0.0001) and 0.10 (95% CI, 0.08-0.13; P<0.0001), respectively. Combination of the 2 miRNAs also provided statistically significant reclassification with a net reclassification improvement of 20.45% (95% CI, 12.73%-28.17%; P<0.0001) and integrated discrimination improvement of 0.16 (95% CI, 0.13-0.20; P<0.0001).
Correlation of Plasma miRNAs With Cardiac Enzymes in Patients With AMI
The correlations between circulating miRNAs and cardiac enzymes were next analyzed in all the patients with AMI (Figure III in the Data Supplement). MiR-320b was significantly correlated with CK (r=-0.155; P=0.023) but not with creatine kinase MB (CKMB) (r=0.03; P=0.625) or cTnI (r=-0.148; Figure 2 . Plasma microRNAs ( miRNAs) profiles in patients with acute myocardial infarction (AMI) and controls. RNA was isolated from the pooled plasma of controls (n=20) and patients with AMI (n=20). A heat map diagram is shown, clustering the differentially expressed miRNAs.
P=0.127). None of the cardiac enzymes was significantly correlated with miR-125b (r=-0.121; P=0.084 for CK; r=-0.103; P=0.096 for CKMB; and r=-0.074; P=0.446 for cTnI).
Gene-Expression Profiles in HUVECs Regulated by MiR-320b and MiR-125b
Accumulating evidence has suggested that besides acting as biomarkers, circulating miRNAs may also act as extracellular communicators and regulate the gene expressions in VECs. 19, 20 Because miR-320b and miR-125b are also expressed in VECs, we hypothesized that the downregulated miRNAs in AMI might be related with the development and progression of atherosclerosis, which is a trigger of myocardial infarction, by regulating gene expressions in VECs. The expression levels of miR-320b/miR-125b in HUVECs after transfection are shown in Figure IV in the Data Supplement. Because the transfection experiments were performed in triplicates, a total of 9 RNA samples were profiled in the microarray experiment. Results suggest that 1042 and 2737 genes were deregulated in HUVECs transfected with miR-320b or miR-125b, respectively (the significant value was false discovery rate, <0.05). Genes without clarified functions were excluded from further analysis. GO mapping analysis shows that besides the translation process, miR-320b also regulated genes relevant to the process of cell proliferation, cell migration, transforming growth factor (TGF)-β signaling, and immune and inflammatory response ( Table IV in the Data Supplement). The differentially expressed genes are enriched in the cardiovascular disease-related pathways, including TGF-β signaling (P=0.0007) and cytokine-cytokine receptor interaction (P=0.02; Table 4 ). Normalized intensities of these genes are summarized in Table V in the Data Supplement. Likewise, upregulation of miR-125b in HUVECs interfered with the expression of genes involved in apoptosis, platelet activation, and inflammatory response (Table IV in the Data Supplement). Normalized intensities of these differentially expressed genes, which were found to be enriched in the pathway of apoptosis (P<0.0001) and the cytokine-cytokine receptor interaction pathway (P=0.0008; Table 4 ), are summarized in Table VI in the Data Supplement.
Plasma Levels of MiR-320b and MiR-125b in Patients With Stable CHD
To illustrate the regulation of miR-320b and miR-125b in the progression of atherosclerosis, we further detected the levels of these 2 miRNAs in patients with stable CHD and compared them with the age and sex-frequency-matched healthy controls and patients with AMI, who were selected from the validation stage I population. The general characteristics of this sample set are shown in Table VII in the Data Supplement. A gradual decrease in the plasma levels of the 2 miRNAs (P trend <0.001 for miR-320b and P trend <0.001 for miR-125b, respectively) was found across categories of healthy control (n=100), stable CHD (n=100), and AMI (n=100; Figure V in the Data Supplement). The plasma levels of these 2 miRNAs were significantly lower in patients with stable CHD than in healthy controls (P=0.004 for miR-320b and P<0.001 for miR-125b, respectively). Of note, they were also significantly lower in patients with AMI when compared with the patients with stable CHD (P<0.001 for miR-320b and P=0.022 for miR-125b, respectively).
Discussion
In this study, we found that levels of plasma miR-320b and miR-125b were lower in patients with AMI when compared with controls in Chinese populations, and lower levels of miR-320b and miR-125b were consistently associated with increased occurrence of AMI. Receiver operating characteristic curve and reclassification analyses suggested that addition of the 2 miRNAs to traditional risk factors and history of medication use might improve the predictive values for AMI. The preliminary functional study further suggested that miR-320b and miR-125b could regulate the expression profiles of genes enriched in several signal transduction pathways critical for CHD in human VECs.
An increasing body of evidence suggests that several cardiacenriched miRNAs, including miR-208a/b, miR-499-5p, and miR-133a/b, can be released into circulation after AMI and may serve as biomarkers for myocardial injury. 13, 21, 22 In line with previous evidence, the results of massively parallel sequencing in our study showed that miR-499-5p, miR-133a, and miR-208b were elevated >2-fold in patients with AMI when compared with controls ( Figure 2) . However, the increase of miR-208a did not reach the threshold of 2-fold change (data are not shown). D'Alessandra et al 21 were unable to detect an elevation in circulating miR-208a levels after AMI AMI indicates acute myocardial infarction; CI, confidence interval; miRNA, microRNA; and OR, odds ratio. *The relative expression level of miRNAs was normalized to cel-miR-39 and calculated by 2 -ΔCt . §Reference group. †Multivariate logistic regression with adjustment for age, sex, smoking, body mass index (BMI), total cholesterol, triglyceride, hypertension, and diabetes mellitus for model 1.
‡Multivariate logistic regression with adjustment for age, sex, smoking, BMI, total cholesterol, triglyceride, hypertension, diabetes mellitus, and history of medication use for model 2.
‖Pooled analysis described the results when validation stages I and II were pooled together. ¶The number of AMI-associated circulating miRNAs, including low miR-320b and low miR-125b. #P trend .
as well. This may be partially attributed to the time points when plasma samples were collected in that study (on average 9 hours after the onset of AMI symptoms) or to the lower levels of miR-208a even after AMI in blood when compared with other muscle-enriched miRNAs, which may be below the detection limit of the protocol used. We reported lower levels of plasma miR-320b and miR-125b in patients with AMI in this study, and the lower levels of miRNAs were associated with an increased occurrence of AMI. The history of medication use was included in the prediction model 2 ( Table 2) to investigate the effect on AMI occurrence because increasing evidence has shown that medication therapy may also alter circulating miRNA levels. 23, 24 Results suggest that the medication use decreased the associations between miRNAs and AMI to a certain degree, but the associations remained significant. Of note, the miRNA levels showed no significant difference in patients with AMI with or without history of medication use before hospital admission, suggesting that the 2 miRNAs are markers of AMI rather than drug use.
It is now well known that circulating miRNAs may be highly correlated with each other, and miRNA panels may offer better sensitivity and specificity for disease diagnosis and, therefore, are more reliable disease biomarkers when compared with single miRNAs. [25] [26] [27] However, we found similarities of the area under the receiver operating characteristic curve and net reclassification improvement values between miR-320b and the 2 combined miRNAs, suggesting that miR-125b might not provide any added predictive value. Therefore, further studies on miRNA global expression patterns are warranted to identify novel miRNAs that can be represented as coexpression networks. MiR-320b was found to be negatively correlated with the cardiac enzyme CK, indicating a potential link between plasma miR-320b and the myocardial injury, whereas it was not the case for miR-125b. Nevertheless, the result is still interesting considering that it may add independent diagnostic value, which needs further investigation.
Because the plasma levels of miR-125b and miR-320b were found to be lower in patients with AMI when compared with controls in our study, we supposed that these miRNAs might not be released from the heart. Fichtlscherer et al 12 previously demonstrated that the plasma levels of several atherosclerosisrelated miRNAs were significantly lower in the patients with stable CHD when compared with healthy controls. Likewise, Zampetaki et al 25 demonstrated that the baseline levels of 3 plasma miRNAs were associated with the incidence of MI. Therefore, circulating miRNAs may also be involved in the pathogenesis of CHD. 28, 29 Previous studies have suggested that circulating miRNAs may act as extracellular communicators because they could be transferred to VECs and regulate atherosclerotic processes. [30] [31] [32] Extracellular miRNAs are especially adept at mediating gene regulation among cells in a microenvironment. 33 In this regard, subintimal inflammation and atherosclerotic lesions, which harbor complex multicellular microenvironments, may be a nexus of miRNA-based signaling. Because endothelial dysfunction is critical for atherosclerosis, 34 we hypothesized that miR-125b and miR-320b might be involved in the pathogenesis of atherosclerosis by regulating gene-expression profiles in VECs. Of note, both miR-125b and miR-320b are expressed in VECs, and their expressions were regulated as a result of cellular signals or environmental cues. 35, 36 The preliminary functional study suggested that the 2 miRNAs could influence several critical signal transduction pathways (Table 3) , including the TGF-β pathway and apoptosis. The TGF-β pathway is commonly disrupted in atherosclerosis. 37 Proliferation and migration of the VECs can also be strongly inhibited by TGF-β. 38, 39 Apoptosis of the VECs is a major determinant of plaque erosion and thrombosis formation, which is a trigger of MI. 40 MiR-125b can regulate apoptosis by targeting transcripts encoding Mcl-1, 41 Bcl-w, 41 IL-6R, 41 and the expression of ≈14 genes inP53 network. 42 Interestingly, the 2 miRNAs may also be involved in the inflammatory response by regulating the cytokine-cytokine receptor interaction pathway (Table 3 ). MiR-125b was previously demonstrated to be involved in the activation of macrophages and inflammatory responses by regulating IRF4 43 and the tumor necrosis factor-α expression. 44 Intriguingly, a study recently reported in line with us showing that circulating miR-320b could be transferred to VECs where it regulated intercellular adhesion molecule-1 expression. 45 In addition, we found that Bax and PPP1CA, 2 differentially expressed genes identified by the gene microarray in our study, have been validated to be the targets of miR-125b and involved in the apoptosis process. 42, 46 Therefore, the functional analyses, although preliminary, may deepen the understanding of the role of circulating miRNAs in atherosclerosis processes and pave the way for further investigations. The role of these 2 miRNAs in the progression of atherosclerosis was further suggested by their gradual decreased levels across categories of healthy control, stable CHD, and AMI in our study. The novel findings may suggest prognostic values of the 2 miRNAs for AMI, which needs further investigation in cohort studies.
This study has several strengths. First, the relatively large sample size provides sufficient statistical power for the multivariate analysis. Second, the associations between plasma miRNAs and the occurrence of AMI were replicated in 2 independent casecontrol studies. Third, the gene-expression profiling by microarray provides a plausible and testable biological explanation for the epidemiological findings in our study. However, 3 major limitations should also be addressed. First, like any case-control studies, potential selection bias may influence the interpretation of the results. Second, the pooling strategy for sequencing in discovery stage, which may have masked the individual heterogeneity, together with the clinical differences between the 3 patient cohorts, may be largely responsible for the inconsistency between the results of massively parallel sequencing and qRT-PCR assays for several validated miRNAs. Third, further investigations are needed to demonstrate the kinetics of miR-320b/miR-125b plasma levels in follow-up data, and the key target genes of the 2 miRNAs also need to be investigated in future studies.
In summary, this study suggests that the plasma levels of miR-320b and miR-125b were associated with the occurrence of AMI. Moreover, the preliminary function analysis suggests that plasma miR-320b and miR-125b may provide useful information on the pathogenesis of AMI, which was further suggested by their gradually decreased levels across categories of healthy controls, patients with stable CHD, and patients with AMI. Further investigations in cohort studies and functional tests are needed to validate our epidemiological findings and to explore the biological relevance of this study.
